Exelixis, Inc. (EXEL) stock
EXELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends January 1
Financials through Q3 FY2026, quarter ended Oct 2, 2026Last filing: 10-Q on Oct 29, 2026Score 18/303% above fair value
$68.29−0.21 (-0.31%)
Close on Nov 18, 2026Market cap $16.66BP/E 20.4Yield –
Exelixis revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Exelixis's revenue for the twelve months ending Oct 2, 2026 was $2.50B, up 9.1% year over year. For fiscal 2025 it was $2.32B, up 7.0% from the year before. Over ten years it grew 51.2% a year on average. The highest annual figure on record is $2.32B in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | $2.32B | +7.0% |
| FY2024 | Jan 3, 2025 | $2.17B | +18.5% |
| FY2023 | Dec 29, 2023 | $1.83B | +13.6% |
| FY2022 | Dec 30, 2022 | $1.61B | +12.3% |
| FY2021 | Dec 31, 2021 | $1.43B | +45.3% |
| FY2020 | Jan 1, 2021 | $987.54M | +2.0% |
| FY2019 | Jan 3, 2020 | $967.78M | +13.3% |
| FY2018 | Dec 28, 2018 | $853.83M | +88.7% |
| FY2017 | Dec 29, 2017 | $452.48M | +136.3% |
| FY2016 | Dec 31, 2016 | $191.45M | +415.0% |
| FY2015 | Dec 31, 2015 | $37.17M | +48.0% |
| FY2014 | Dec 31, 2014 | $25.11M | -19.9% |
| FY2013 | Dec 31, 2013 | $31.34M | -34.0% |
| FY2012 | Dec 31, 2012 | $47.45M | -83.6% |
| FY2011 | Dec 31, 2011 | $289.64M | +56.5% |
| FY2010 | Dec 31, 2010 | $185.05M | +21.9% |
| FY2009 | Dec 31, 2009 | $151.76M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Oct 2, 2026 | $658.70M | +10.2% |
| Q2 FY2026 | Jul 3, 2026 | $628.69M | +10.6% |
| Q1 FY2026 | Apr 3, 2026 | $610.81M | +10.0% |
| Q4 FY2025 | Jan 2, 2026 | $598.66M | +5.6% |
| Q3 FY2025 | Oct 3, 2025 | $597.76M | +10.8% |
| Q2 FY2025 | Jul 4, 2025 | $568.26M | -10.8% |
| Q1 FY2025 | Apr 4, 2025 | $555.45M | +30.6% |
| Q4 FY2024 | Jan 3, 2025 | $566.76M | +18.2% |
| Q3 FY2024 | Sep 27, 2024 | $539.54M | +14.3% |
| Q2 FY2024 | Jun 28, 2024 | $637.18M | +35.6% |
| Q1 FY2024 | Mar 29, 2024 | $425.23M | +4.0% |
| Q4 FY2023 | Dec 29, 2023 | $479.65M | +13.1% |
| Q3 FY2023 | Sep 29, 2023 | $471.92M | +14.6% |
| Q2 FY2023 | Jun 30, 2023 | $469.85M | +12.0% |
| Q1 FY2023 | Mar 31, 2023 | $408.79M | +14.8% |
| Q4 FY2022 | Dec 30, 2022 | $423.92M | -6.0% |
| Q3 FY2022 | Sep 30, 2022 | $411.74M | +25.4% |
| Q2 FY2022 | Jul 1, 2022 | $419.43M | +8.9% |
| Q1 FY2022 | Apr 1, 2022 | $355.98M | +31.7% |
| Q4 FY2021 | Dec 31, 2021 | $451.14M | +67.1% |
| Q3 FY2021 | Oct 1, 2021 | $328.42M | +42.1% |
| Q2 FY2021 | Jul 2, 2021 | $385.18M | +48.4% |
| Q1 FY2021 | Apr 2, 2021 | $270.23M | +19.1% |
| Q4 FY2020 | Jan 1, 2021 | $270.05M | +12.4% |
| Q3 FY2020 | Oct 2, 2020 | $231.09M | -14.9% |
| Q2 FY2020 | Jul 3, 2020 | $259.48M | +8.0% |
| Q1 FY2020 | Apr 3, 2020 | $226.92M | +5.3% |
| Q4 FY2019 | Jan 3, 2020 | $240.31M | +5.1% |
| Q3 FY2019 | Sep 27, 2019 | $271.70M | +20.5% |
| Q2 FY2019 | Jun 28, 2019 | $240.28M | +29.1% |
| Q1 FY2019 | Mar 29, 2019 | $215.49M | +0.8% |
| Q4 FY2018 | Dec 28, 2018 | $228.60M | +90.4% |
| Q3 FY2018 | Sep 28, 2018 | $225.40M | +47.8% |
| Q2 FY2018 | Jun 29, 2018 | $186.11M | +88.0% |
| Q1 FY2018 | Mar 30, 2018 | $213.72M | +164.2% |
| Q4 FY2017 | Dec 29, 2017 | $120.07M | +54.8% |
| Q3 FY2017 | Sep 30, 2017 | $152.51M | – |
| Q2 FY2017 | Jun 30, 2017 | $99.01M | – |
| Q1 FY2017 | Mar 31, 2017 | $80.89M | – |
| Q4 FY2016 | Dec 31, 2016 | $77.58M | – |
See a number that looks wrong?